source
- Boston Scientific lowers full-year revenue outlook as restructuring plan targets slowing growthBoston Scientific announced on July 29 that it is cutting its 2026 full-year organic revenue growth forecast to 5-6%, down from the prior 6.5-8% range. The revision follows a second consecutive qu…
- Arvinas CEO outlines strategy to rebuild pipeline after lead asset departureIn a recent episode of the Denatured podcast, Arvinas President and CEO Randy Teel discussed how the company is shifting focus to an early‑stage pipeline after its lead asset was out‑licensed or di…